Dr. Michael Lock, MD
Claim this profileLondon Health Sciences Centre, London Regional Cancer Program
Studies Cancer
Studies Hepatocellular Carcinoma
3 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Michael Lock, MD is currently running
TACE + SBRT
for Liver Cancer
Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients. A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. The purpose of this study is to find out if TACE alone versus TACE plus SBRT is better for you and your liver cancer.
Recruiting2 awards Phase 317 criteria
Hormone Therapy + SBRT + Enzalutamide
for Prostate Cancer
This adaptive phase II/III randomized trial is designed to demonstrate that eradication of oligometastases by SBRT is a promising and emerging way to delay disease progression and postpone second line systemic therapies in castration-resistant prostate cancer (CRPC) patients. Only CRPC patients with an oligometastatic recurrence will be eligible to take part in this trial. All participating patients will receive either the standard of care (i.e. LHRH agonist in combination with the new generation of hormonal therapy [Enzalutamide]) or the experimental treatment (i.e. LHRH agonist in combination with the new generation of HT [Enzalutamide] plus the additional SBRT treatment). The patients will undergo different evaluations before treatment, such as imaging to confirm oligometastatic recurrence and blood tests. Patients will be stratified according to the location of metastasis (visceral [with or without bone metastases] vs. bone metastases alone) and PSA doubling time (≤ 3 vs. > 3 months). As per the standard of care, patients will have PSA testing performed every 6-12 weeks and re-imaging at 6, 9, 12, 18 and 24 months or at PSA progression, whichever occurs first.
Recruiting3 awards Phase 2 & 3
More about Michael Lock, MD
Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Michael Lock, MD has experience with
- Stereotactic Body Radiation Therapy
- Transarterial Chemoembolization
- Triptorelin
- Leuprolide Acetate
- Goserelin Acetate
- Enzalutamide
Breakdown of trials Michael Lock, MD has run
Hepatocellular Carcinoma
Prostate Cancer
Liver Metastases
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Lock, MD specialize in?
Michael Lock, MD focuses on Cancer and Hepatocellular Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Michael Lock, MD currently recruiting for clinical trials?
Yes, Michael Lock, MD is currently recruiting for 3 clinical trials in London Ontario. If you're interested in participating, you should apply.
Are there any treatments that Michael Lock, MD has studied deeply?
Yes, Michael Lock, MD has studied treatments such as Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, Triptorelin.
What is the best way to schedule an appointment with Michael Lock, MD?
Apply for one of the trials that Michael Lock, MD is conducting.
What is the office address of Michael Lock, MD?
The office of Michael Lock, MD is located at: London Health Sciences Centre, London Regional Cancer Program, London, Ontario N6A 5W9 Canada. This is the address for their practice at the London Health Sciences Centre, London Regional Cancer Program.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.